Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Ta

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
ESMO Open|February 13, 2024
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphomaY M Geurts, S I M Neppelenbroek, B M P Aleman, et al.
Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
ESMO Open|February 13, 2024
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphomaY M Geurts, S I M Neppelenbroek, B M P Aleman, et al.
Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.
Pageof 5